Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 5, 2011, Pages 311-316

  Duygu, Fazilet ^a   Tekin Koruk, Suda ^a   Aksoy, Nurten ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Hepatitis B; Paraoxonase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC ACTIVE HEPATITIS; CHRONIC DISEASE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CARRIER; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; SPECTROPHOTOMETRY; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CARRIER STATE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED;

HEPATITIS B VIRUS;

EID: 80052822945     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20473     Document Type: Article

References (31)

1. Nevin DN, Ambon A, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988;43:230-238.
2. Furlong CE, Richter RJ, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 2001;34:475-481.
3. Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for the determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem 2006;52:453-457.
4. Canales A, Sanchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc) 2003;121:537-548.
5. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-834.
6. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283.
7. Baskol G, Demir H, Baskol M, et al. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 2005;38:951-955.
8. Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2008;196:270-274.
9. Sutherland WH, de Jong SA, Walker RJ. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: An in vitro study. Nephrol Dial Transplant 2004;19:75-82.
10. Maddrey WC. Hepatitis B: An important public health issue. J Med Virol 2000;361:2.
11. Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment. Clin Chim Acta 2007;386:114-115.
12. Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases, 6th edition. Philadelphia: Churchill Livingstone, 2005. p 1426-1441.
13. Ferre N, Camps J, Prats E, et al. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:262-268.
14. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005;11:7351-7354.
15. Ferre N, Marsillach J, Camps J, et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006;45:51-59.
16. Anna SF, Lok L, McMahon BJ. American Association for the Study of Liver Diseases (AASLD) Practice Guidelines Chronic Hepatitis B: Update 2009.
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
18. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-154.
19. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
20. Mackness MI. Why plasma should not be used to study paraoxonase. Atherosclerosis 1998;136:195-196.
21. Koziel MJ, Thio CL. Hepatitis B virus and Hepatitis delta virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases, 7th edition. Philadelphia: Churchill Livingstone, 2010. p 2059-2086.
22. Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Virol 2005;34:125-129.
23. Cavdar C, Sifil A, Camsari T. Reactive oxygen particules and antioxidant defense. Turkish J Nephrol Dial Transplant 1997;3-4:92-95.
24. Lipincott W. Paraoxonase a cardioprotective enzyme: Continuing issues. Curr Opin Lipidol 2004;15:261-267.
25. Ali EM, Shehata HH, Ali-Labib R, Esmail Zahra LM. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. Clin Biochem 2009;42:1394-1400.
26. Keskin M, Dolar E, Dirican M, et al. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation with disease severity. Int Med J 2009;39:243-248.
27. Aslan M, Horoz M, Nazligul Y, et al. Serum paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis. Int J Clin Pract 2008;62:1050-1055.
28. Ozols J. Isolation and complete covalent structure of liver micrasomal paraoxonase. Biochem J 1999;338:265-272.
29. Marsillach J, Camps J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol 2009;14:3.
30. Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases, 7th edition. Philadelphia: Churchill Livingstone, 2010. p 1577-1592.
31. Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999;353:468-469.